Comparison of intracoronary selected CD 133+ bone marrow stem cells in cardiac recovery after acute myocardial infarct and left ventricular dysfunction: COMPARE-AMI a randomized controlled double blind clinical study

Phase 2

Recruiting

• Conditions: Myocardial infarct; Heart failure; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12609001045202
• Lead Sponsor: Miltenyi Biotech Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-12-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

acute ST-elevation myocardial infarct successfully reperfused by means of coronary stent implantation and demonstrated a substantial persistent LV dysfunction defined by a LVEF <50% but >25% on echocardiography obtained within 48 hours after the successful reperfusion therapy.

Exclusion Criteria

known previous myocardial infarct, cardiogenic shock, chronic cardiomyopathy, liver disease, renal failure, concomitant disease with a life expectancy of less than 1 year, alcohol or drug dependency, contraindication for bone marrow (BM) aspiration, blood transfusion in the previous 24 hours, hematopoietic disease, chronic inflammatory disease, malignancy, stroke in the previous 3 months or transient ischemic attack in the previous 24 hours.

Study & Design

• Study Type: Interventional
• Study Design: Not specified